Cambridge AI Coronavirus Vaccine Passes Human Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- DIOSynVax (DVX) Ltd reported that its AI‑designed universal coronavirus vaccine was safe and well tolerated in a Phase I trial of 39 healthy volunteers.
- University of Cambridge researchers used AI to create a “super‑antigen” targeting shared features of Sarbeco coronaviruses, eliciting immune responses against SARS‑CoV‑2, SARS and several bat viruses.
- The trial generated measurable immune responses against multiple coronaviruses, including SARS‑CoV‑2, SARS and related bat viruses with pandemic potential.
- Journal of Infection published the study, noting it is the first human test of a vaccine whose active ingredient was created entirely through computer simulations.
- Researchers said the same AI design strategy could eventually be applied to other virus families such as Ebola and influenza.
Why it matters: Public health agencies gain a broadly protective vaccine platform that could reduce future pandemic costs, while manufacturers may see reduced need for frequent strain‑specific updates.
